Screening for Active Small Molecules in Mitochondrial Complex I Deficient Patient’s Fibroblasts, Reveals AICAR as the Most Beneficial Compound

Anna Golubitzky1*, Phyllis Dan1*, Sarah Weissman1, Gabriela Link1, Jakob D. Wikstrom2, Ann Saada1*

1 Monique and Jacques Roboh Department of Genetic Research, Department of Genetics and Metabolic Diseases, Hadassah, Hebrew University Medical Center, Jerusalem, Israel, 2 Department of Endocrinology and Metabolism, Hadassah, Hebrew University Medical Center, Jerusalem, Israel

Abstract

Congenital deficiency of the mitochondrial respiratory chain complex I (CI) is a common defect of oxidative phosphorylation (OXPHOS). Despite major advances in the biochemical and molecular diagnostics and the deciphering of CI structure, function assembly and pathomechanism, there is currently no satisfactory cure for patients with mitochondrial complex I defects. Small molecules provide one feasible therapeutic option, however their use has not been systematically evaluated using a standardized experimental system. In order to evaluate potentially therapeutic compounds, we set up a relatively simple system measuring different parameters using only a small amount of patient’s fibroblasts, in glucose free medium, where growth is highly OXPHOS dependent. Ten different compounds were screened using fibroblasts derived from seven CI patients, harboring different mutations. 5-Aminimidazole-4-carboxamide ribotide (AICAR) was found to be the most beneficial compound improving growth and ATP content while decreasing ROS production. AICAR also increased mitochondrial biogenesis without altering mitochondrial membrane potential (Δψ). Fluorescence microscopy data supported increased mitochondrial biogenesis and activation of the AMP activated protein kinase (AMPK). Other compounds such as; bezafibrate and oltipraz were rated as favorable while polyphenolic phytochemicals (resverastrol, grape seed extract, genistein and epigallocatechin gallate) were found not significant or detrimental. Although the results have to be verified by more thorough investigation of additional OXPHOS parameters, preliminary rapid screening of potential therapeutic compounds in individual patient’s fibroblasts could direct and advance personalized medical treatment.

Introduction

The congenital disorders of mitochondrial oxidative phosphorylation (OXPHOS) are common inborn errors of metabolism, with an incidence of 1:5000–8000 live births [1,2]. Among these, deficiency of mitochondrial respiratory chain complex I (NADH CoQ oxidoreductase, EC 1.6.5.3) is the most common and accounts for one-third of all patients referred for OXPHOS evaluation [3].

Complex I (CI), is the first complex of the mitochondrial respiratory chain. It is a large multimeric complex composed of 45 structural subunits; seven are encoded by the mitochondrial DNA (mtDNA) while 38 structural subunits and a number of CI assembly factors are all nuclear encoded [4]. Some of the subunits are post transcriptionally modified by phosphorylation, acetylation or glutathionylation [5–7].

Disease causing mutations have been identified in all mtDNA encoded subunits as well as in a number of the nuclear encoded (mtDNA) while 38 structural subunits and a number of CI assembly factors. Some of the subunits are post transcriptionally modified by phosphorylation, acetylation or glutathionylation [5–7].

Disease causing mutations have been identified in all mtDNA encoded subunits as well as in a number of the nuclear encoded subunits and assembly factors [8,9].

The clinical phenotype of complex I deficiency is varied and includes severe neonatal lactic acidosis, Leigh disease, cardiomyopathy-encephalopathy, hepatopathy-tubulopathy, leukodystrophy with macrocephaly optic atrophy, cerebellar ataxia, retinitis pigmentosa and growth retardation [10]. The extensive damage observed in patients with complex I deficiency is most probably due to energy depletion and to over-production of reactive oxygen species (ROS) with subsequent initiation of the apoptotic cascade [11–13].

Despite major advances in the biochemical and molecular diagnostics and the deciphering of the CI structure, function, assembly and pathomechanism, there is currently no satisfactory cure for patients with mitochondrial complex I defects. Small molecules provide one feasible therapeutic option, however their use has not been systematically evaluated using a standardized experimental system, and treatment has been based on “trial and error” [14–16]. Vitamins (vitamin K, riboflavin, B1,B2), cofactors (CoQ, carnitine, creatine), and ROS scavengers (vitamin E, CoQ10), have all been administered to improve OXPHOS, by providing alternate substrates, removing lactate accumulation (by dichloroacetate) and ameliorating oxidative damage (reviewed by Dimauro and Mancuso) [15–16]. The favorable effect of Coenzyme Q10 supplementation for CoQ deficiency is undispu-
table however the efficacy of riboflavin has been demonstrated only in a few cases of complex I deficiency [11,17]. For other compounds, results have been equivocal or were reported anecdotally. In recent years, a large number of compounds with therapeutic potential have been described. These include polyphenolic phytochemicals such as resveratrol, grape seed extract, green tea extract and genistein. Resveratrol is a natural phytoalexin found in a wide variety of plant species, including grapes. Among its numerous properties, resveratrol has been reported to have anti-oxidant activities and to activate the genetic expression of key genes in energy metabolism such as peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α). Resveratrol and grape seed extract (a proanthocyanidin) were demonstrated to have beneficial effects on mitochondrial function in several experimental models [18-20]. Green tea polyphenols attenuated mitochondrial dysfunction in glucose deprived gloial cell cultures [21]. Genistein is a soy derived isoflavone which has been evaluated in substrate reduction therapy for mucopolysaccharidoses and was also reported to induce mitochondrial biogenesis [22-23].

In addition to polyphenols, other substances such as compounds enhancing energy metabolism, antioxidants and chemical chaperones are potentially beneficial. Representative of this type are 5-Aminomidazole-4-carboxamide ribotide (AICAR), olitipraz, bezafibrate and sodium phenylbutyrate.

AICAR is a pharmacological activator of AMP activated protein kinase (AMPK). This heterotrimeric protein complex plays a key role in the regulation of energy homeostasis. The kinase is activated by an elevated AMP/ATP ratio caused by cellular and environmental stress, such as heat shock, hypoxia and ischemia. AMPK regulates energy expenditure by modulating NAD⁺ dependent-type III deacetylase SIRT1, resulting in the deacetylation of downstream targets including PGC1α forhead box O1 and 3 transcription factors [24]. Notably, Thr172 phosphorylation on the AMPK protein is a prerequisite for its activation [25]. Olitipraz is a 1,2-dithiole-3-thione compound with antioxidant properties. Oltipraz has also been demonstrated to reduce apoptosis in cells with chemically inhibited CI by exerting its cytoprotective effect through AMPK [26-27]. Bezafibrate is an agonist of peroxisome proliferator-activated receptors (PPARs) stimulating oxidative metabolism and has a documented positive effect on mitochondria. On the other hand, fenofibrate was reported to have a negative effect on CI [16,28-29]. Sodium phenyl butyrate is a, histone deacetylase (HDAC) inhibitor, affecting protein phosphorylation and relief of endoplasmic reticulum stress. Although the mechanism of action of this compound is poorly defined, it has been found to be beneficial in a number of diseases including cancer, neurodegenerative diseases and metabolic diseases [30-33]. All of the above mentioned compounds have been documented to exert positive effects, however to our knowledge, they have not been systematically screened in OXPHOS deficient patient’s cells together in the same system.

The objectives of this research were two-fold; to develop an in vitro system for the rapid screening of multiple compounds using a small amount of fibroblasts from individual patients and to identify compounds with a therapeutic potential for mitochondrial complex I deficiency.

Materials and Methods

Subjects

Fibroblasts previously derived (with informed consent, approved by the IRB), from six patients with mitochondrial respiratory chain complex I (CI) deficiency, were included in the study. Most of these patients have been previously described and all harbored known mutations in different nuclear encoded complex I subunits: NDUF52[34,35], NDUF84 or assembly factors; COOBF66 (NDUF-FAF6)[35], C20ORF7[36], FOXRED1 [37,38] B172.2.L (NDUF-A12L)[39]. Their clinical and biochemical data are briefly summarized in Table 1.

Tissue cultures

Fibroblasts were maintained in DMEM (Biological Industries, Kibbutz Beit Haemek, Israel) medium containing 4.5 g glucose per liter and supplemented with 10% fetal calf serum, 50 µg/ml uridine, and 110 µg/ml pyruvate (GLU, permissive medium) at 37°C, 5%CO₂.

For assessment of various compounds, 3×10⁵ cells/100 µl were seeded in triplicate on three identical 96 well microtiter plates. The following day, the medium was removed, the cells were washed once with phosphate buffered saline (PBS) and replaced with 100 µL GLU medium or a restrictive glucose-free DMEM medium (Biological Industries, Kibbutz Beit Haemek, Israel) supplemented with 10% dialyzed fetal calf serum and 5 mM galactose (GAL) with or without additives as follows: 0.5 mM AICAR (Tocris, Bioscience, Bristol UK); 50 µM Genistein (GENI) (Cayman Chemicals Ann Arbor MI USA; 100 µM, Bezafibrate (BEZA); 10 µM Oltipraz (OLTP); 5uM Resveratrol (RSV); 10 uM Epigallocatechin gallate (EGCG)(Sigma-Aldrich, Steinheim, Germany) or grape seed extract (GSE) (Tianjin Jianfeng Natural Products, China). 72h post-treatment the tissue cultures were analyzed for growth, reactive oxygen species (ROS) and ATP. (Biological Industries, Kibbutz Beit Haemek, Israel).

Assays

Cell growth was measured by a colorimetric method based on the staining of basophilic cellular compounds (mainly nucleic acids, independent on redox status) with methylene blue at λmax, as modified by Jones et al [39]. For the evaluation methylene blue assay (MB) control cells were serially diluted in GLU medium, seeded in six wells. After 48h triplicate wells were measured by MB and triplicate wells were subjected to viable count by trypan blue. For evaluation of time course, 3×10⁵ control cell and cells from a patient were seeded in GLU medium. The following day the medium was replaced either with fresh GLU or GAL. The amount of cells was quantified by MB after 24 h, 48 h, 72 h and 144 h (medium was replaced with fresh after 72 h).

The intracellular ROS production was measured using 2′,7′-dichlorodihydrofluorescein diacetate (DCF) (Biotium Harvard CA USA)[40]. Briefly, growth medium was removed and replaced by 100uL/well of 10 µM DCF in PBS-Ca²⁺ Mg²⁺ (PBS containing 0.9 mM calcium chloride and 0.5 mM magnesium chloride) and the plates were incubated for 20 min at 37°C, 5%CO₂. After removal of DCF, the ROS production was monitored for 20 minutes in 100ul PBS-Ca²⁺ Mg²⁺ at λex 485 nm and λem 520 nm. ATP content was measured by luciferin-luciferase using the ATPlite® luminescence assay system according to the manufacturer’s instruction (Perkin Elmer Waltham MA, USA).

Luminescence, fluorescence and absorbance measurements were performed with a Synergy HT microplate reader (Bio-Tek instruments, Vinoosky VT, USA).

Relative fluorescence units (RFU) and relative luminescence units (RLU) were calculated by normalizing to growth as measured by MB in parallel wells for each separate experiment. The mean of all experiments was calculated and compared to that of GAL without additive (containing vehicle only). All experiments were performed in triplicate wells on at least two separate
occasions. Statistical significance (p < 0.05) was calculated by 2-tailed student’s t-test. Data were also visualized using the matrix2png software [41]. http://www.bioinformatics.ubc.ca/matrix2png/.

Table 1. Patient data.

| patient/ mutated gene | C20ORF7 | NDUF52 | NDUF54 | C6orf66 (NDUFAF4) | FOXRED1 | B17.2L (NDUFA12L) |
|-----------------------|---------|--------|--------|-------------------|---------|-------------------|
| age of onset          | 1 year  | 6 months | 3 months | birth             | 4 months | 8 months         |
| clinical details      | Leigh’s syndrome, mild lactic acidosis, died at 6 years | optic atrophy, hypodense basal ganglia, cardio-myoopathy, severe lactic acidosis, died at 2 years | lactic acidosis, seizures | encephalo-myoopathy, severe lactic acidosis, died at 2 months | Micro-cephaly, encephalo-pathy, lactic acidosis | Hypotonia, motor delay, horizontal nystagmus, bilateral optic atrophy, abnormal MRI, mild lactic acidosis |
| residual muscle enzymatic activities | CI 54% CV 4% | CII within normal range | CI 17% C II-V within normal range | CI 25% C II-V within normal range | CI 14% C II-V within normal range | CI 7% C II-V within normal range |
| reference             | 36      | 34,11  | unpublished | 35,12             | 37      | 37,13            |

doi:10.1371/journal.pone.0026883.t001

Fluorescence microscopy

Fibroblasts were seeded at 3.5 × 10⁴ cells/ml in GLU medium. The following day the medium was replaced with GLU, GAL or GAL containing 0.5 mM AICAR for 72hrs. For assessment of

Figure 1. Measurement of growth, ROS and ATP in control and patient fibroblasts. Fibroblast from control and patient (NDUF52) were grown in microtiter wells in GLU, GAL or GAL supplemented with AICAR. The amount of control cells, measured by methylene blue (MB) at A₆₂₀ was compared to viable count by trypan blue at 72h (A). Growth of control and patient cells was measured at 24, 48, 72h and 144h by MB at A₆₂₀ (B, C). Growth with AICAR was assessed at 72h (C). ROS measured by DCF at 72h is expressed as relative fluorescent units (RFU) divided by the amount of cells measured by MB at A₆₂₀ (D). ATP was measured at 72h by luciferin-luciferase is expressed as relative luminescence units (RLU) divided by the amount of cells measured by MB at A₆₂₀ (E). Values are presented as mean of triplicates +/- standard deviation. *p < 0.05.
doi:10.1371/journal.pone.0026883.g005
mitochondrial content and $\Delta \Psi$, the cells grown in 35 mm glass bottom tissue culture, plates and incubated with 200 nM Mitotracker Green FM (MTG) and 50 nM tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes Eugene, Oregon USA), for 90 and 45 minutes respectively at 37°C, 5%CO$_2$ [42]. For phospho-AMPK (pAMPK) immunocytochemistry and Mitotracker stain, cells were grown on fibronectin coated coverslips and incubated with 1.5 µM MitoTracker Red CM-H2XRos (MTR, Molecular Probes Eugene, Oregon USA) for 45 minutes at 37°C, 5%CO$_2$, chased for 30 minutes with the respective growth medium, fixed with 4% paraformaldehyde in PBS, permeabilized with 0.25% Triton X-100, stained with 1.75 Phospho-AMPK$\alpha$-(Thr172) primary antibody (Cell Signalling Technology Inc.Denver MA, USA) and subsequently, with Dylight 488 conjugated anti rabbit secondary antibody (Jackson Thermo Scientific, Rockford IL, USA). Cells were visualized by fluorescent confocal microscopy (10×4). Image analysis was done with MetaMorph image analysis software. All micrographs in a series were taken under the same conditions.

Oxygen consumption

Oxygen consumption rate (OCR) was measured using an XF24 extracellular flux analyzer (Seahorse Biosciences, North Billeric, MA, USA). Fibroblast were seeded at 12–14 x 10$^3$ cells/well in 500 µl in GLU medium on an XF 24 well plate at 37°C, 5%CO$_2$. The following day the medium was replaced with GLU, GAL or GAL containing 0.5 mM AICAR. After 72hrs the growth medium was changed to 500 µl unbuffered DMEM medium with the same constituents as above (GLU, GAL or GAL with AICAR) and incubated at 37°C for 1h for equilibration before the measurements. After 10 minutes of OCR baseline measurements, 50 µl carbonylcyanide-3-chlorophenylhydrazone (CCCP) was injected to reach a working concentration of 20 µM and the maximal OCR was measured. Background OCR was measured after injection of rotenone and antimycin to a final concentration of 5 µM each. After the experiment, cell content was estimated by MB and OCR was calculated as OCR minus background divided by MB.

Figure 2. The effect of various compounds on growth, ROS and ATP in control and patient fibroblasts. Fibroblast from three separate controls and seven patients (C20orf7, NDUFS2, NDUFS4, C6orf66, FOXRED1 and B17.2L) were grown in microtiter wells in GLU or GAL medium or in GAL medium, supplemented with one of eight various compounds (BEZA, AICAR, OLTI, SBP, RSV, GENI, EGGCG, GSE) in GAL for 72hrs. Growth was assessed by MB (A). ROS was measured by DCF and normalized to MB (B). ATP was measured by luciferin-luciferase and normalized to MB (C). Values (A–C) are presented as relative values graphically presented as heatmaps representing the mean of triplicates performed on at least 2 separate occasions. Growth in GAL without additives was set as the value of 1 (black). Values < 1 are presented in increasingly green and values > 1 in increasingly red. All parameters are summarized in (D) and evaluated as a significantly positive (+), negative (−) or nonsignificant (ns) effect. Increased values for growth and ATP were regarded as positive while negative for increased ROS. Positive only is shaded in red, negative only in green, nonsignificant in dark grey and mixed responses in gray.

doi:10.1371/journal.pone.0026883.g001
All patients presented in infancy, were severely affected and diagnosed with isolated CI deficiency in muscle, with the exception of patient C20orf7 who had a combined partial deficiency of both CI and CIV. All patients were molecularly defined with mutations either in a nuclear encoded CI subunit or in a CI assembly factor (Table 1). Fibroblasts from these patients were initially assessed for growth, ROS production and ATP content. Preliminary experiments demonstrated that 3×10⁵ cells/well was sufficient to obtain clear readings and reproducible results (Fig. 1A). As it was not possible to measure all parameters in the same well, 3 identical plates treated in parallel were measured in each experiment. Still it was possible to screen ten variables in triplicate wells using less than 3×10⁵ cells (less than a T25 confluent flask). In order to relate values to cell content, we initially evaluated the MB assay and compared those values to values obtained by viable counts. There was a linear relationship between the number of cells and methylene blue absorption (Fig. 1A). As MB staining is much more feasible to perform than viable counting of hundreds of microtiter wells, we therefore continued to evaluate growth by the MB assay. Accordingly, all RFU and RLU values were normalized to MB in order to compare values per cell content. To establish a suitable time frame for the experiments we compared the time course of growth in GLU and GAL. While patient’s cell growth was comparable to control cells in GLU media, impaired growth of patient’s cells in GAL media was evident after 72h (Fig. 1B). Therefore, 72h was chosen as the optimal time frame for examining compounds.

A typical experiment with control and patient fibroblasts is depicted in Fig. 1C–D. Since it is difficult to present and summarize a large number (1000<) of measurements, the summary of all data are depicted as a heatmaps in Fig. 2 A–C. (The values on GAL were set at 1 in the middle of the scale (black). Values less than 1 were increasingly green and higher then 1 increasingly red).

The growth in GAL medium relative to GLU was slightly decreased in control fibroblasts while growth was markedly decreased in all patients cells (Fig. 2A). These results were anticipated, as GAL medium is devoid of substrates for glycolysis and therefore growth is highly dependent on the oxidation of fatty acids (derived from FCS) by intact OXPHOS for energy production [43]. Intracellular ROS production was generally increased in GAL medium. The increase was evident in one control and four of the patients (Fig. 2B). In patient Ndufs2 the ratio was reversed, presumably because of the severe growth defect in GAL (Fig. 1B). This is also be the reason for the very low ATP.
content in GAL medium (Fig. 1C). Notably all control cells had higher ATP content in GAL medium, reflecting the higher efficiency of ATP production by OXPHOS than by glycolysis. This was not the case for four of the six patients and reflects the CI defect. Notably cells with a high ATP content in GAL were derived from controls or patients C2ORF7 and NDUFS4 with a relatively high residual CI activity in muscle (Table 1, Fig. 2C).

Next, the effect of various compounds was examined. The compounds tested were polyphenols, and other compounds with reported effects on ROS production and mitochondrial biogenesis. Untreated cells in the presence of vehicle (DMSO), cells grown in GAL and control cells were included in each experiment. It should be noted that the examination of the effect of different compounds required a prior set of experiments initially based on data available from the literature, in order to optimize conditions with respect to medium and concentration. As these experiments required larger quantities of cells, they were performed in normal cells and in some of the patient’s cells. From the preliminary data, we concluded that the effect of additives was best demonstrated under stressful conditions i.e. in GAL medium compared to growth with vehicle only in the same medium (Fig. 1B). The effect of each compound on each cell on each of the above parameter is presented in Fig. 2A–C. Many compounds either lacked any effect or had a beneficial effect on growth. For example, bezafibrate increased growth in C20ORF7 approaching that in GLU medium. On the contrary, genistein, EGCG and grapeseed extract. The effect of genistein was unclear since it had a positive effect on only FOXRED1 cells while negatively affected the control.

In order to create a simplified overview, we rated a compound as beneficial when it increased growth, ATP and decreased ROS compared to the values on GAL. The evaluation was designated with a plus sign for each favorable parameter while a negative effect was designated with a minus sign. When no parameter was significantly altered by a compound it was designated non significant (ns). Mixed effects were designated plus/minus (Fig. 2D). To summarize, AICAR was the most favorable compound with positive effects on several parameters in five out of six patient cells. Bezafibrate was also beneficial to two patient’s cells but to a lesser extent. Interestingly, Otopraz had a beneficial effect on half the patient’s. Although sodium phenylbutyrate slightly increased ROS in some cells, the overall score was positive in fifty percent of the patients (Fig. 2D). No positive but many mixed and some negative effects were observed with resveratrol, EGCG and grapeseed extract. The effect of genistein was unclear because it had a positive effect on only FOXRED1 cells while negatively affected the control.

In order to further investigate the effect of AICAR we conducted an extended study of a representative cell (NDUFS2) to include the evaluation of mitochondrial content and mitochondrial Δψ by fluorescence microscopy and oxygen consumption (Figs. 3 and 4). Mitochondrial content estimated by MTG was found slightly but significantly increased in both control and patients cells in GAL medium. AICAR induced a clear increase in mitochondrial content only in the patient’s cells (Fig. 3A and B). The alteration of TMRE stain relative to mitochondrial content in the presence of AICAR was minor and not significant, indicating that Δψ was not substantially affected (Fig. 3A and C). While uncoupled oxygen consumption was increased in GAL medium, AICAR had no significant effect (Fig. 4A and B) although the basal uncoupled OCR was somewhat, not significantly relative to basal OCR in the patient’s cells (Fig. 4B).

To examine the downstream effect of AICAR, we performed immunostaining with an antibody towards Thr172 phosphorylated AMPK (pAMPK) while co-staining with MTR (Fig. 5A–C).
While clearly present in control cells, pAMPK stain was very weak in NDUFS2 cells grown on GLU (Fig. 5A and B). AICAR supplementation caused a marked and significant increase of pAMPK in the patients cells. Mitotracker stain was increased in patient’s cells on GAL but approached control values in the presence of AICAR (Fig. 5A and C).

Discussion

The search for therapeutic agents for mitochondrial complex I deficiency and OXPHOS defects in general, is seriously hampered by the lack of a standardized model system for evaluating treatment. Many studies focused on small groups of patients simultaneously treated with several agents leading to difficulties in interpreting data and patient responses to therapy in vivo. Documented in vitro assays usually focus on a specific compound or a specific parameter using a relatively large sample size (11–13,17).

We developed an accessible and relatively simple system in 96 well plates assessing a number of different parameters by the use of one instrument. This enabled us screen multiple compounds on a small amount of fibroblasts simultaneously while measuring a number of different parameters. The small sample size allowed the use of primary cells which is advantageous not only for practical reasons but also because immortalized cells frequently do not retain their original phenotype and thus respond differently than primary cells (personal experience).

The fibroblasts for this study were chosen to represent CI deficiency, the most common OXPHOS defect. The cells were derived from patients with different CI defects, in order to assess individual responses to different compounds. Indeed the responses differed in some instances between the patients. This is exemplified by bezafibrate which was beneficial for NDUFS2 ATP content but not for C20ORF7, emphasizing the need to evaluate compounds on an individual basis. Individual evaluation is especially important when attempting to treat disorders where the mitochondrial function is already a priori compromised. The necessity to measure different parameters was evident when observing the effect of the various polyphenolic cytochemicals (resveratrol, EGCG, grape seed extract and genetin) included in the study. Generally they decreased ROS formation which is advantageous, but concomitantly decreased growth and ATP content. Although some of these results contradict studies reporting positive effects previously mentioned in the introduction,

Figure 5. The effect of AICAR on pAMPK and mitotracker red stain in control and patient fibroblasts. Control and patient fibroblasts were grown on coverslips in GLU or GAL medium and in GAL supplemented with 0.5 mM AICAR (GAL+AICAR) for 72 hrs. Cells were then incubated with mitotracker red (MTR), fixed, stained with anti pAMPK antibodies and visualized by fluorescent (pAMPK) secondary antibodies. The coverslips were examined by confocal fluorescent microscopy (10×40). A: depicts a representative micrograph of pAMPK stain in green and MTR stain in red. The graphs represent green intensity per cell (B) and red intensity per cell (C) +/- standard deviation (*p<0.05). All micrographs were taken under the same conditions. doi:10.1371/journal.pone.0026883.g004
they are actually in accord with other studies reporting that some polyphenols can induce cancer cell death though mitochondrial membrane depolarization and apoptosis [44,45]. On the other hand, AICAR was found to be the most promising compound with no detected negative effect and an overall positive score in most of the patient’s cells. The positive effect on mitochondrial biogenesis was also clearly visible by the MTG stain while the ΔΨm was not affected. Immunocytochemistry also supported activation of AMPK. Remarkably AICAR has been given intravenously to humans in clinical trials for the treatment of hyperinsulinemia [46]. Recently AICAR was also reported to be favorable in cytochrome c oxidase deficiency [47,48].

Apparently there is a discrepancy between the mixed effect of resveratrol and the positive effect of AICAR since they both activate the same SIRT1, PGC1α axis pathway [18,24,49]. The underlying mechanism for this inconsistency remains unclear and requires further thorough investigation. Nevertheless, we suggest that the positive effects of resveratrol on patients cells might be masked by some additional negative effects. Notably, resveratrol was reported to inhibit the mitochondrial FoF1 ATPsynthase (complex V) and oxygen consumption while depleting ATP content [50,51]. In fact, resveratrol alone is suggested to act as an anticancer compound by targeting mitochondria through the activation of pro-apoptotic pathways [52]. It is therefore conceivable that resveratrol might exert a negative effect on some parameters on some individual patient’s cells with an a priori mitochondrial dysfunction. Apart from AICAR, olipizpr and bezafibrate disclosed a general positive effect, but to a lesser extent. Sodium phenylbutyrate increased ATP but also caused a slight increase of ROS and therefore the use of this compound in OXPHOS defects could be questionable. We detected only a partial correlation between individual responses in fibroblasts and residual enzymatic complex I activity in muscle, genotype or clinical presentation (Table and Fig. 2). Moreover, the clinical correlation between fibroblasts responses and patients response to treatment has only been proved in a few instances and further correlation studies are warranted [11,17]. Nevertheless patient’s fibroblasts provide an accessible tissue for testing individual responses to additives and drugs [48].

Taken together, we present an accessible and relative simple system using a small amount of patient’s fibroblasts for screening potential treatments in OXPHOS defects. This enables the screening to be performed on an individual basis while measuring a number of different parameters which are not limited to the measurement of a specific respiratory chain complex. Consequently the system has a wide applicability, and could be used for other defined and undefined OXPHOS defects. The authors are aware that this system is suitable for preliminary screening only, and that the results will have to be verified by precise investigation of additional parameters and mechanisms by other methods measuring OXPHOS by enzymatic assays and expression analysis on the protein and mRNA levels. Nonetheless these assays are more complex and require a larger number of cells making them much less applicable for screening purposes. We propose that rapid preliminary screening of potential therapeutic compounds in individual patient’s fibroblasts could direct and advance personalized medical treatment.

Acknowledgments

We thank Prof. Orly Elpeleg, Hadassah-Hebrew University Medical Center, for clinical and molecular data, and Prof.Yuvol Dor, Hebrew University, for antibodies.

Author Contributions

Conceptualized and designed the experiments: AG LS AS JDW. Performed the experiments: AG PD SW AS. Analyzed the data: AG PD AS JDW. Contributed reagents/materials/analysis tools: AS GL. Wrote the paper: AS.

References

1. Schaefer AM, Taylor RW, Turnboll DM, Chinery PF (2004) The epidemiology of mitochondrial disorders—present, present and future. Biochim Biophys Acta 1659: 115–120.
2. Sliauskas D, Halliday J, Thorburn DR (2003) Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 126: 1905–1912.
3. Kirby DM, Crawford M, Cleary MA, Dunnett N, Dippel X, et al. (1999) Respiratory chain complex I deficiency: an underdiagnosed energy generation disorder. Neurology 52: 1253–1264.
4. Carroll JF, Fearnley IM, Skehel JM, Shannon RJ, Hirst J, et al. (2006) Bovine complex I is a complex of 45 different subunits. J Biol Chem 281: 32724–32727.
5. Chen R, Fearnley IM, Prak-Chew SY, Walker JE (2004) The phosphorylation of subunits of complex I (from bovine heart mitochondria). J Biol Chem 279: 26036–26043.
6. Ahn BH, Kim HS, Song S, Lee IH, Liu J, et al. (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci 105: 14447–14452.
7. Hurd TR, Requejo R, Filipovska A, Brown S, Prime TA, et al. (2008) Complex I within oxidatively stressed bovine heart mitochondria is glutathionylated on Cys-531 and Cys-704 of the 75-kDa subunit: potential role of CYS residues in decreasing oxidative damage. J Biol Chem 283: 24801–24813.
8. Janssen RJ, Niijmans LG, van den Heuvel LP, Smethink JA (2006) Mitochondrial complex I: structure, function and pathology. J Inherit Metab Dis 29: 499–511.
9. Mckenzie M, Ryan MT (2010) Assembly factors of human mitochondrial respiratory chain complex I and their defects in disease. IUBMB Life 62: 497–502.
10. Pitkanen S, Feigenbaum A, Laframboise R, Robinson BH (1996) NADH-ubiquinone reductase (complex I): deficiency: heterogeneity in phenotype and biochemical findings. J Inherit Metab Dis 19: 675–680.
11. Bar-Meir A, Elpeleg ON, Saada A (2001) Effect of various agents on adenosine triphosphate production in mitochondrial respiratory chain complex I deficiency. J Pediatr 139: 868–870.
12. Saada A, Bar-Meir M, Belaiche C, Miller C, Elpeleg O (2004) Evaluation of enzymatic assays and compounds affecting ATP production in mitochondrial respiratory chain complex I deficiency. Anal Biochem 335: 66–72.
13. Verkaart S, Koopman WJ, van Enst-de Vries SE, Niijmans LG, van den Heuvel LW, et al. (2007) Superoxide production is inversely related to complex I activity in inherited complex I deficiency. Biochim Biophys Acta 1772: 373–381.
14. Briere JJ, Chretien D, Benit P, Rustin P (2004) Respiratory chain defects: what do we know for sure about their consequences in vivo? Biochim Biophys Acta 1659: 172–7.
15. DiMauro S, Mancuso M (2007) Mitochondrial diseases: therapeutic approaches. Biocell Rex 27: 125–137.
16. DiMauro S (2010) Pathogenesis and treatment of mitochondrial myopathies: recent advances. Am J Adv 29: 333–338.
17. Röting A, Appelkvist EL, Geromel V, Chretien D, Koldzic M, et al. (2000) Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356: 391–393.
18. Lagouge M, Aegnaa C, Gerhart-Hines Z, Meziane H, Liner C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109–1122.
19. Pin C, Tillement JP, Bertrand A, Morin D (2003) Resveratrol protects against cold ischemia-warm reoxygenation-induced damages to mitochondria and cells in rat liver. Eur J Pharmacol 528: 162–168.
20. Pajuelo D, Díaz S, Quaresma H, Fernández-Iglesias A, Muleo M, et al. (2011) Acute Administration of Grape Seed Procyanidin Extract Modulates Energetic Metabolism in Skeletal Muscle and BAT Mitochondria. J Agric Food Chem 59: 4279–4287.
21. Panicker KS, Polansky MM, Anderson RA (2009) Green tea polyphenols attenuate glial swelling and mitochondrial dysfunction following oxygen-glucose deprivation in cultures. Nutr Neurosci 12: 105–13.
22. Kloska A, Jakobkiewicz-Barczak J, Naracyzk M, Barczak-Majkutevicz Z, Wieczorek A (2011) Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis 26: 1–8.
23. Rasbach KA, Schnellmann RG (2008) Isoflavones promote mitochondrial biogenesis. J Pharmacol Exp Ther 325: 536–543.
24. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056–1060.
25. Hardie DG (2004) The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci 117: 3479–3487.
26. Shin SM, Kim SG (2009) Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners. Mol Pharmacol 75: 242–253.
27. Kwon YN, Shin SM, Cho HJ, Kim SG (2009) Oxidized metabolites of oltipraz exert cytoprotective effects against arachidonic acid through AMP-activated protein kinase-dependent cellular antioxidant effect and mitochondrial protection. Drug Metab Dispos 37: 1187–1197.
28. Wenz T, Wang X, Marini M, Morales CT (2010) A metabolic shift induced by a PPAR agonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2010 in press. PMID: 21129152.
29. Brummair B, Lest A, Staniek K, Gras F, Scharf N, et al. (2004) Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 311: 109–114.
30. Burlina AB, Ogier H, Korall H, Trefz FK (2001) Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab 72: 351–355.
31. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, et al. (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drug 25: 131–138.
32. Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, et al. (2002) C6ORF66 is an assembly factor of mitochondrial complex I. Am J Hum Genet 82: 32–38.
33. Xiao C, Giacca A, Lewis GF (2011) Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. Diabetes 60: 918–924.
34. Loeflin J, Elpeleg O, Smeitink J, Smets R, Stockler-Ipsiroglu S, et al. (2001) Mutations in the complex I NDUFAS2 gene of patients with cardiomyopathy and mitochondrial encephalopathy. Ann Neurol 49: 195–201.
35. Saada A, Edvardson E, Shaag A, Chung WK, Segel R, et al. (2008) NDUFAS6 is an assembly factor of mitochondrial complex I. Am J Hum Genet 82: 32–38.
36. Saada A, Edvardson E, Shaag A, Chung WK, Segel R, et al. Combined OXPHOS complex I and IV defect, due to mutated complex I assembly factor C200RFT. J Inherit Metab Dis, in press. DOI: 10.1007/s10545-011-9348-y.
37. Fassone E, Duncan AJ, Taunaman JW, Pagnamenta AT, Sadowski MI, et al. (2010) FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathies. Hum Mol Genet 2010 19: 4837–4847.
38. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, et al. (2006) Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 130: 1115–23.
39. Jones CN, Miller C, Trenenbaum A, Spremulli LL, Saada A (2009) Antibiotic effects on mitochondrial translation and in patients with mitochondrial translational defects. Mitochondrion 9: 429–437.
40. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, et al. (2006) Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55: 120–127.
41. Pauli R, Noble WS (2003) Matrix2png: A Utility for Visualizing Matrix Data. Bioinformatics 19: 295–296.
42. Wang T, Si Y, Shihai OS, Si H, Schultz V, et al. (2010) Respiration in adipocytes is inhibited by reactive oxygen species. Obesity (Silver Spring) 18: 1493–502.
43. Robinson BH (1996) Use of fibroblast and lymphoblast cultures for detection of respiratory chain defects. Methods Enzymol 264: 454–464.
44. Qamuno S, Das M, Haldar S, Ban A (2005) Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 26: 955–967.
45. Sánchez Y, Arraza D, Fernández C, de Blas E, Aller P (2008) Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p53-AMPK, AMPK). Int J Cancer 125: 1205–14.
46. Bosselaar M, Snuits P, van Looon Lj, Tack CJ (2010) Intravenous AICAR During Hyperinsulinemia Induces Systemic Hemodynamic Changes but Has No Local Metabolic Effect. J Clin Pharmacol. in press. PMID: 2114905147.
47. Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggi M, et al. (2011) In vivo correction of COX deficiency by activation of the AMPK/PGC-1α Axis. Cell Metab 14: 90–99.
48. Saada A (2011) The use of individual patient’s fibroblasts in the search for personalized treatment of nuclear encoded OXPHOS diseases. Mol Med Metab. In press. doi: 10.1016/j.mymet.2011.07.016.
49. Lagrouge, M., Argmann C, Grhart-Hines Z, Mezaine H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127: 1–14.
50. Zheng J, Ramirez VD (2000) Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 130: 1115–23.
51. Szkudelska K, Nogowski L, Szkudelski T (2011) Resveratrol and genistein as adenosine triphosphate-depleting agents in fat cells. Metabolism 60: 720–729.
52. Wernier CE (2011) Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol. In press. doi: 10.1002/jcp.22788.
53. Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, et al. (2011) Resveratrol production of complex I and IV defect, due to mutated complex I assembly factor C200RFT. J Inherit Metab Dis, in press. DOI: 10.1007/s10545-011-9348-y.
54. Fassone E, Duncan AJ, Taunaman JW, Pagnamenta AT, Sadowski MI, et al. (2010) FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy. Hum Mol Genet 2010 19: 4837–4847.